BlueSky Immunotherapies GmbH Report issue

For profit Phase 1
Founded: Vienna Austria (2016)

Organization Overview

First Clinical Trial
2020
NCT04490512
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

BlueSky Immunotherapies GmbH

Active Ingredients

Drugs in Phase 1 Trials (1)

flubhpve6e7 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Papillomavirus Infections (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1